spacer
home > ebr > summer 2002 > preventing risk becoming a crisis
PUBLICATIONS
European Biopharmaceutical Review

Preventing Risk Becoming a Crisis

Timing has conspired to bring biopharmaceutical companies into the risk transfer arena just as the insurance market is at its least receptive to such risks. This article will highlight the driving factors and the change in management approach needed to negotiate this business hurdle, which will be new to many companies.When two independent industries both undergo radical and fundamental shifts in the make-up of their own revenue base, the results will be dramatic. Such is the current interface between the emerging biopharmaceutical industry and the retrenching insurance industry.


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
By Howard Pearson, a Director and Head of the Science and Technology Team at The Miller Insurance Group

Howard Pearson is a Director of The Miller Insurance Group, where he heads up the science and technology team.
He is responsible for leading Millers' relationship with the biopharmaceutical industry and the UK Bio Industry Association. Howard holds a Fellowship of the Chartered Insurance Institute and is Chairman of the British Insurance Brokers Association's South East Region.

spacer
Howard Pearson
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

MedPharm announce expansion of partnership with Palvella Therapeutics in developing a new treatment for the debilitating rare disease, pachyonychia congenita

MedPharm Ltd have announced the expansion of their partnership with Palvella Therapeutics, Inc., a Philadelphia-based biopharmaceutical company focused on developing and commercialising therapies for debilitating, rare genetic diseases. To date, MedPharm has employed its world-renowned specialist formulation expertise to support Palvella’s development of a novel, high-strength rapamycin topical formulation for application to the skin (PTX 022) as a disease-modifying treatment for pachyonychia congenita (PC). Most recently, MedPharm has made arrangements to manufacture the clinical (IMP) batches for use in Palvella’s upcoming Phase 2/3 clinical study.
More info >>

White Papers

Crunch Time: The Impact of Serialisation Requirements on Packaging Operations

PCI Pharma Services

The deadlines for including unique product identifiers on prescription drugs is putting a strain on multiple parts of the industry, much of which is ill-prepared to meet the target. Here, we look to the experience of a company that is ahead of the curve for lessons on how to manage and ease the transition to serialisation.
More info >>

 
Industry Events

SAPHEX 2019

23-24 October 2019, GALLAGHER CONVENTION CENTRE, 10 RICHARDS DRIVE, HALFWAY HOUSE, MIDRAND, 1685, SOUTH AFRICA

SAPHEX 2019 will be held on the 23rd-24th October at the Gallagher Convention Centre, Johannesburg, South Africa.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement